

# Gabriel Cabot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5483972/publications.pdf>

Version: 2024-02-01

53  
papers

3,442  
citations

136740

32  
h-index

155451

55  
g-index

56  
all docs

56  
docs citations

56  
times ranked

3031  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>Pseudomonas aeruginosa</i> Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3091-3099.	1.4	197
2	Genetic Markers of Widespread Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> High-Risk Clones. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6349-6357.	1.4	189
3	The Versatile Mutational Resistome of <i>Pseudomonas aeruginosa</i> . <i>Frontiers in Microbiology</i> , 2018, 9, 685.	1.5	181
4	Evolution of <i>Pseudomonas aeruginosa</i> Antimicrobial Resistance and Fitness under Low and High Mutation Rates. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1767-1778.	1.4	170
5	Overexpression of AmpC and Efflux Pumps in <i>Pseudomonas aeruginosa</i> Isolates from Bloodstream Infections: Prevalence and Impact on Resistance in a Spanish Multicenter Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1906-1911.	1.4	168
6	Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 658-663.	1.3	157
7	Influence of Virulence Genotype and Resistance Profile in the Mortality of <i>Pseudomonas aeruginosa</i> Bloodstream Infections. <i>Clinical Infectious Diseases</i> , 2015, 60, 539-548.	2.9	153
8	Pan- $\beta$ -Lactam Resistance Development in <i>Pseudomonas aeruginosa</i> Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4771-4778.	1.4	138
9	<i>Pseudomonas aeruginosa</i> carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2022-2027.	1.3	132
10	Evolution of the <i>Pseudomonas aeruginosa</i> mutational resistome in an international Cystic Fibrosis clone. <i>Scientific Reports</i> , 2017, 7, 5555.	1.6	117
11	Alterations of OprD in Carbapenem-Intermediate and -Susceptible Strains of <i>Pseudomonas aeruginosa</i> Isolated from Patients with Bacteremia in a Spanish Multicenter Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1703-1713.	1.4	111
12	Predicting antimicrobial resistance in <i>Pseudomonas aeruginosa</i> with machine learning-enabled molecular diagnostics. <i>EMBO Molecular Medicine</i> , 2020, 12, e10264.	3.3	111
13	Genomics and Susceptibility Profiles of Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> Isolates from Spain. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	108
14	Biological Markers of <i>Pseudomonas aeruginosa</i> Epidemic High-Risk Clones. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5527-5535.	1.4	104
15	Deciphering the Resistome of the Widespread <i>Pseudomonas aeruginosa</i> Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7415-7423.	1.4	99
16	Spanish nationwide survey on <i>Pseudomonas aeruginosa</i> antimicrobial resistance mechanisms and epidemiology. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1825-1835.	1.3	92
17	Wide Dispersion of ST175 Clone despite High Genetic Diversity of Carbapenem-Nonsusceptible <i>Pseudomonas aeruginosa</i> Clinical Strains in 16 Spanish Hospitals. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2905-2910.	1.8	76
18	Role of <i>Pseudomonas aeruginosa</i> Low-Molecular-Mass Penicillin-Binding Proteins in AmpC Expression, $\beta$ -Lactam Resistance, and Peptidoglycan Structure. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3925-3934.	1.4	75

#	ARTICLE	IF	CITATIONS
19	Clonal Dissemination, Emergence of Mutator Lineages and Antibiotic Resistance Evolution in <i>Pseudomonas aeruginosa</i> Cystic Fibrosis Chronic Lung Infection. <i>PLoS ONE</i> , 2013, 8, e71001.	1.1	69
20	Impact of AmpC Derepression on Fitness and Virulence: the Mechanism or the Pathway?. <i>MBio</i> , 2016, 7, .	1.8	62
21	NagZ Inactivation Prevents and Reverts $\beta$ -Lactam Resistance, Driven by AmpD and PBP 4 Mutations, in <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3557-3563.	1.4	61
22	<i>In Vivo</i> Emergence of Resistance to Novel Cephalosporin- $\beta$ -Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 $\beta$ -Lactamase (OXA-539) in Sequence Type 235 <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	61
23	Environmental Microbiota Represents a Natural Reservoir for Dissemination of Clinically Relevant Metallo- $\beta$ -Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5376-5379.	1.4	55
24	Activity of Imipenem-Relebactam against a Large Collection of <i>Pseudomonas aeruginosa</i> Clinical Isolates and Isogenic $\beta$ -Lactam-Resistant Mutants. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	54
25	A Standard Numbering Scheme for Class C $\beta$ -Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	50
26	AmpG Inactivation Restores Susceptibility of Pan- $\beta$ -Lactam-Resistant <i>Pseudomonas aeruginosa</i> Clinical Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1990-1996.	1.4	47
27	Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory <i>Pseudomonas aeruginosa</i> Isolates Expressing Combinations of Most Relevant $\beta$ -Lactam Resistance Mechanisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6407-6410.	1.4	47
28	Evolution of the <i>Pseudomonas aeruginosa</i> Aminoglycoside Mutational Resistome <i>In Vitro</i> and in the Cystic Fibrosis Setting. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	44
29	A trade-off between oxidative stress resistance and DNA repair plays a role in the evolution of elevated mutation rates in bacteria. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2013, 280, 20130007.	1.2	40
30	Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the <i>Caenorhabditis elegans</i> / <i>Pseudomonas aeruginosa</i> Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	39
31	Molecular mechanisms driving the <i>in vivo</i> development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR <i>Pseudomonas aeruginosa</i> infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 91-100.	1.3	38
32	<i>In Vitro</i> and <i>In Vivo</i> Activities of $\beta$ -Lactams in Combination with the Novel $\beta$ -Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo- $\beta$ -Lactamase-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	35
33	Targeting the permeability barrier and peptidoglycan recycling pathways to disarm <i>Pseudomonas aeruginosa</i> against the innate immune system. <i>PLoS ONE</i> , 2017, 12, e0181932.	1.1	32
34	Impact of multidrug resistance on the pathogenicity of <i>Pseudomonas aeruginosa</i> : <i>in vitro</i> and <i>in vivo</i> studies. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 368-374.	1.1	30
35	Deciphering $\beta$ -lactamase-independent $\beta$ -lactam resistance evolution trajectories in <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3322-3331.	1.3	27
36	Molecular and biochemical insights into the <i>in vivo</i> evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR <i>Pseudomonas aeruginosa</i> infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3209-3217.	1.3	26

#	ARTICLE	IF	CITATIONS
37	Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1474-1478.	1.3	26
38	Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating <i>Pseudomonas aeruginosa</i> Chronic Respiratory Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2912-2922.	1.4	25
39	In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2508-2515.	1.3	24
40	Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a <i>Pseudomonas aeruginosa</i> ST175 Clone. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	22
41	Association between <i>Pseudomonas aeruginosa</i> O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3217-3220.	1.3	18
42	<i>N</i> -Acetylcysteine Selectively Antagonizes the Activity of Imipenem in <i>Pseudomonas aeruginosa</i> by an OprD-Mediated Mechanism. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3246-3251.	1.4	16
43	Comparative analysis of <i>in vitro</i> dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in <i>Pseudomonas aeruginosa</i> XDR high-risk clones. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 957-968.	1.3	14
44	Characterization of AmpC $\beta$ -lactamase mutations of extensively drug-resistant <i>Pseudomonas aeruginosa</i> isolates that develop resistance to ceftolozane/tazobactam during therapy. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 474-478.	0.3	13
45	Understanding the acute inflammatory response to <i>Pseudomonas aeruginosa</i> infection: differences between susceptible and multidrug-resistant strains in a mouse peritonitis model. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 198-203.	1.1	12
46	Comparative Analysis of Peptidoglycans From <i>Pseudomonas aeruginosa</i> Isolates Recovered From Chronic and Acute Infections. <i>Frontiers in Microbiology</i> , 2019, 10, 1868.	1.5	12
47	Weighting the impact of virulence on the outcome of <i>Pseudomonas aeruginosa</i> bloodstream infections. <i>Clinical Microbiology and Infection</i> , 2020, 26, 351-357.	2.8	11
48	Nosocomial outbreak linked to a flexible gastrointestinal endoscope contaminated with an amikacin-resistant ST17 clone of <i>Pseudomonas aeruginosa</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1837-1844.	1.3	11
49	<i>In vitro</i> evolution of cefepime/zidebactam (WCK 5222) resistance in <i>Pseudomonas aeruginosa</i> : dynamics, mechanisms, fitness trade-off and impact on <i>in vivo</i> efficacy. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2546-2557.	1.3	11
50	Profiling the susceptibility of <i>Pseudomonas aeruginosa</i> strains from acute and chronic infections to cell-wall-targeting immune proteins. <i>Scientific Reports</i> , 2019, 9, 3575.	1.6	10
51	Draft Genome Sequence of the Quorum-Sensing and Biofilm-Producing <i>Pseudomonas aeruginosa</i> Strain Pae221, Belonging to the Epidemic High-Risk Clone Sequence Type 274. <i>Genome Announcements</i> , 2015, 3, .	0.8	5
52	Whole-genome sequence-guided PCR for the rapid identification of the <i>Pseudomonas aeruginosa</i> ST175 high-risk clone directly from clinical samples. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 945-949.	1.3	2
53	Characterization of AmpC $\beta$ -lactamase mutations of extensively drug-resistant <i>Pseudomonas aeruginosa</i> isolates that develop resistance to ceftolozane/tazobactam during therapy. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2020, 38, 474-478.	0.2	1